These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 11675061)

  • 1. Selective seratonin 1F (5-HT(1F)) receptor agonist LY334370 for acute migraine: a randomised controlled trial.
    Goldstein DJ; Roon KI; Offen WW; Ramadan NM; Phebus LA; Johnson KW; Schaus JM; Ferrari MD
    Lancet; 2001 Oct; 358(9289):1230-4. PubMed ID: 11675061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy, tolerability and safety of oral eletriptan and ergotamine plus caffeine (Cafergot) in the acute treatment of migraine: a multicentre, randomised, double-blind, placebo-controlled comparison.
    Diener HC; Jansen JP; Reches A; Pascual J; Pitei D; Steiner TJ;
    Eur Neurol; 2002; 47(2):99-107. PubMed ID: 11844898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spotlight on almotriptan in migraine.
    Keam SJ; Goa KL; Figgitt DP
    CNS Drugs; 2002; 16(7):501-7. PubMed ID: 12056924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute treatment of migraine with the selective 5-HT1F receptor agonist lasmiditan--a randomised proof-of-concept trial.
    Ferrari MD; Färkkilä M; Reuter U; Pilgrim A; Davis C; Krauss M; Diener HC;
    Cephalalgia; 2010 Oct; 30(10):1170-8. PubMed ID: 20855362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and tolerability of lasmiditan, an oral 5-HT(1F) receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study.
    Färkkilä M; Diener HC; Géraud G; Láinez M; Schoenen J; Harner N; Pilgrim A; Reuter U;
    Lancet Neurol; 2012 May; 11(5):405-13. PubMed ID: 22459549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Almotriptan: a review of its use in migraine.
    Keam SJ; Goa KL; Figgitt DP
    Drugs; 2002; 62(2):387-414. PubMed ID: 11817980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting to 5-HT1F receptor subtype for migraine treatment: lessons from the past, implications for the future.
    Mitsikostas DD; Tfelt-Hansen P
    Cent Nerv Syst Agents Med Chem; 2012 Dec; 12(4):241-9. PubMed ID: 22934751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of rizatriptan 10 mg vs. naratriptan 2.5 mg in migraine.
    Bomhof M; Paz J; Legg N; Allen C; Vandormael K; Patel K
    Eur Neurol; 1999; 42(3):173-9. PubMed ID: 10529545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials.
    Ferrari MD; Roon KI; Lipton RB; Goadsby PJ
    Lancet; 2001 Nov; 358(9294):1668-75. PubMed ID: 11728541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eletriptan in acute migraine: a double-blind, placebo-controlled comparison to sumatriptan. Eletriptan Steering Committee.
    Goadsby PJ; Ferrari MD; Olesen J; Stovner LJ; Senard JM; Jackson NC; Poole PH
    Neurology; 2000 Jan; 54(1):156-63. PubMed ID: 10636142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute treatments: some blind alleys.
    Ramadan NM
    Curr Med Res Opin; 2001; 17 Suppl 1():s71-80. PubMed ID: 12463283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short-term efficacy and safety of lasmiditan, a novel 5-HT
    Hou M; Xing H; Li C; Wang X; Deng D; Li J; Zhang P; Chen J
    J Headache Pain; 2020 Jun; 21(1):66. PubMed ID: 32503415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Speed of onset, efficacy and tolerability of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double-blind, placebo-controlled study.
    Dodick D; Brandes J; Elkind A; Mathew N; Rodichok L
    CNS Drugs; 2005; 19(2):125-36. PubMed ID: 15697326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Naratriptan.
    Massiou H
    Curr Med Res Opin; 2001; 17 Suppl 1():s51-3. PubMed ID: 12463278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The safety and efficacy of the 5-HT 1F receptor agonist lasmiditan in the acute treatment of migraine.
    Raffaelli B; Israel H; Neeb L; Reuter U
    Expert Opin Pharmacother; 2017 Sep; 18(13):1409-1415. PubMed ID: 28749698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sustained responses to lasmiditan: Results from post-hoc analyses of two Phase 3 randomized clinical trials for acute treatment of migraine.
    Doty EG; Krege JH; Jin L; Raskin J; Halker Singh RB; Kalidas K
    Cephalalgia; 2019 Oct; 39(12):1569-1576. PubMed ID: 31266353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of a change in lasmiditan dose on efficacy and safety in patients with migraine.
    Clemow DB; Hochstetler HM; Dong Y; Hauck P; Peres MFP; Ailani J
    Postgrad Med; 2021 May; 133(4):449-459. PubMed ID: 33730977
    [No Abstract]   [Full Text] [Related]  

  • 18. Almotriptan, a new anti-migraine agent: a review.
    Gras J; Llenas J; Jansat JM; Jáuregui J; Cabarrocas X; Palacios JM
    CNS Drug Rev; 2002; 8(3):217-34. PubMed ID: 12353056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Meta-analysis examining the efficacy and safety of almotriptan in the acute treatment of migraine.
    Chen LC; Ashcroft DM
    Headache; 2007 Sep; 47(8):1169-77. PubMed ID: 17883521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The 5-HT1F receptor agonist lasmiditan as a potential treatment of migraine attacks: a review of two placebo-controlled phase II trials.
    Tfelt-Hansen PC; Olesen J
    J Headache Pain; 2012 Jun; 13(4):271-5. PubMed ID: 22430431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.